NEW YORK, Dec. 27, 2025, 3:10 p.m. ET — Market closed
Bristol-Myers Squibb Company (NYSE: BMY) stock is heading into the weekend with U.S. equity markets closed, leaving investors to digest the latest batch of institutional ownership updates and re-check near-term catalysts that could matter when trading resumes Monday. The pharmaceutical giant finished the most recent regular session (Friday) essentially flat, while broader benchmarks also showed little movement—typical of late-December, liquidity-thinner trading. 1
BMY stock price recap: where shares last traded
BMS’ investor relations quote page shows BMY at $54.64 as of Dec. 26 at 4:00 p.m. ET, down $0.07 (-0.13%) on the day. Friday’s session range was $54.38 to $55.04 on volume of about 9.57 million shares. The stock’s 52-week range is $42.52 to $63.33, placing BMY roughly 13.7% below its 52-week high and about 28.5% above its 52-week low (based on the latest quoted price and published 52-week range). 1
MarketBeat’s analyst-forecast page also showed extended-hours activity after Friday’s close around $54.72 (as of 7:59 p.m. ET), a modest uptick that doesn’t change the bigger picture: BMY is currently trading in a range where investors are weighing income appeal (dividend yield) against longer-term growth questions (pipeline execution and the post–patent-cliff transition). 2
The most recent BMY news: last 24–48 hours (institutional filings dominate)
With no major company press release landing over the past day or two, the freshest BMY-specific headlines have largely come from 13F-related coverage and other ownership-position updates tied to third-quarter reporting.
Here are the notable BMY items published in the last 24–48 hours:
- Meyer Handelman Co. reported reducing its position by 9.9%, selling 52,438 shares, and retaining 475,518 shares (reported value about $21.45 million). 3
- Cwm LLC reported increasing its stake by 34.5%, adding 206,970 shares to reach 806,549 shares (reported value about $36.38 million). 4
- Brookstone Capital Management reported boosting its stake by 205.6%, adding 82,486 shares to reach 122,613 shares (reported value about $5.53 million). 5
- Trust Co. of Toledo NA OH reported increasing its stake by 231.2%, adding 110,815 shares to reach 158,750 shares (reported value about $7.16 million). 6
- Pacer Advisors reported reducing its stake by 4.2%, selling 410,744 shares, while still holding 9,304,698 shares (reported value about $419.64 million). 7
- Donald L. Hagan LLC reported a new position of 20,550 shares (reported value about $927,000). 8
Important context for investors: these are backward-looking snapshots of positions reported for the third quarter, not real-time “tape” buying or selling. Still, the steady stream of ownership updates can influence sentiment—especially for large-cap healthcare names like BMY where valuation, dividends, and institutional sponsorship often shape the shareholder base.
Wall Street view: analyst forecasts, targets, and the debate around “value vs. visibility”
On the forecast side, MarketBeat’s compilation shows a consensus rating of “Hold” based on 21 analysts, with an average 12-month price target of $54.62—essentially implying a flat outlook around the latest trading level. MarketBeat lists a high target of $68 and a low target of $37, highlighting just how wide the fundamental debate remains. 2
Recent analyst notes highlighted in market coverage include:
- Guggenheim reiterating a Buy rating with a $62 price target amid attention on competition in obstructive hypertrophic cardiomyopathy (oHCM) and scrutiny of differentiation versus a newly approved rival therapy. 9
- Bank of America Securities upgrading BMY from Neutral to Buy (as reported by Nasdaq/Fintel), underscoring the view that BMY’s risk/reward can look compelling after the stock’s reset and amid its cash-return profile. 10
The split is straightforward:
- The bull case leans on BMY’s scale, cash flow, and dividend, plus confidence that newer products and pipeline assets can offset legacy erosion over time.
- The bear case focuses on pricing pressure, execution risk, and uncertainty around post-peak revenue replacement—especially as investors model the next several years.
Dividend and policy catalysts investors are watching into year-end
Dividend: new $0.63 quarterly payout and the key dates
Bristol-Myers Squibb announced in December that its board declared a $0.63 quarterly dividend, payable Feb. 2, 2026, to shareholders of record Jan. 2, 2026—and noted this increase marked the company’s 17th consecutive year of dividend increases. 11
Why it matters right now: the calendar is tightening. With markets closed today (Saturday), income-focused investors often start mapping out their next-session plan—particularly when an ex-dividend window is approaching and when year-end rebalancing can move “defensive yield” names.
Drug-pricing deal focus: Eliquis and Medicaid
Another major narrative hanging over large-cap pharma into 2026 is the evolving U.S. pricing environment. In a Dec. 19 corporate announcement, BMS said it reached an agreement with the U.S. government under which Eliquis (apixaban) would be made available for free to Medicaid starting Jan. 1, 2026, alongside other commitments (including donations tied to supply chain resilience and other access provisions). 12
BMS CEO Christopher Boerner, Ph.D. said the company is taking “direct action” to improve access for vulnerable patients while continuing to invest in the U.S.—a statement that investors will weigh against questions around longer-term net pricing and margin implications. 12
The next major scheduled catalyst: Q4 earnings date is set
BMS has already put a firm date on its next major investor event: the company said it will report fourth-quarter 2025 results on Thursday, Feb. 5, 2026, with a conference call at 8:00 a.m. ET. 13
For investors, that matters now because late December and early January positioning often anticipates the next earnings window—especially for companies where guidance and pipeline updates can drive multiple expansion (or compression).
Bigger-picture fundamentals investors keep circling back to
Even as the last 48 hours’ headlines revolve around ownership updates, BMY’s longer-running investment debate is still anchored to fundamentals:
- In its most recent quarterly reporting cycle, Reuters noted BMS posted Q3 2025 revenue of $12.22 billion, helped by products including cancer immunotherapy Opdivo and blood thinner Eliquis, while also continuing to manage pressure from generic competition in parts of its portfolio. 14
- That same Reuters report highlighted the company’s balancing act: supporting growth brands and pipeline investments while navigating the revenue headwinds that come with maturing blockbuster franchises. 14
What investors should know before the next session (Monday)
Because the market is closed today, Monday’s open becomes the next real “decision point.” Here’s what many BMY watchers focus on heading into the next session:
- Expect quieter trading conditions to persist
Late-December trading can amplify small moves—especially in large-cap defensives where positioning shifts can matter more than day-to-day news flow. - Don’t over-interpret the weekend headline mix
The last 24–48 hours’ BMY headlines are heavily skewed toward 13F/ownership updates, which are informative but not the same as real-time conviction buying. - Keep the dividend calendar in view
The declared $0.63 quarterly dividend and the Jan. 2, 2026 record date are near-term reference points for income-oriented shareholders. 11 - Policy headlines can move “mega-cap pharma” sentiment fast
Any follow-on details, commentary, or peer-company actions related to drug access and pricing—especially around major products like Eliquis—can shift how investors model 2026. 12 - Earnings are the next hard catalyst
With the Feb. 5, 2026 Q4 results date already announced, incremental news between now and then can influence expectations—but the next official reset for guidance and narrative will likely come from that report and call. 13
Bottom line: Bristol-Myers Squibb stock enters the weekend largely unchanged, with the freshest headlines centered on institutional filings rather than new operational developments. The near-term setup for BMY into the next session is defined by a familiar mix: dividend visibility and defensive qualities on one side, and policy/pipeline execution questions on the other—while Wall Street’s consensus “Hold” posture suggests investors may need a clearer catalyst to break the stock out of its current range. 2
